QuidelOrtho Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brian J. Blaser
- Full Time Employees
- 6,500
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 9975 Summers Ridge Road San Diego CA United States of America 92121
- IPO Date
- Feb 1, 1991
- CIK
- 0001906324
- Website
- quidelortho.com
- Similar Companies
- Business
- QuidelOrtho Corporation (Nasdaq: QDEL), founded in 1979 and headquartered in San Diego, California, develops, manufactures and markets in vitro diagnostic technologies for point-of-care settings, clinical laboratories and transfusion medicine worldwide, serving customers in over 140 countries across North America, Europe, the Middle East, Africa, China and other regions. The company offers a comprehensive portfolio of products and services including visually-read lateral flow assays such as QuickVue for infectious diseases, reproductive health and cardiac markers; Sofia fluorescent immunoassay analyzers and tests; direct fluorescent antibody tests; molecular diagnostics via LYRA real-time PCR assays and the forthcoming LEX Diagnostics platform; clinical chemistry and immunodiagnostic systems like VITROS; donor screening with Ortho Summit, VERSEIA and VITROS systems; pre-transfusion testing through ORTHO VISION analyzers and ORTHO CONNECT software; semi-automated immunohematology solutions including ORTHO Workstation and ORTHO OPTIX Reader; and Ortho Care services and informatics for lab efficiency. In recent developments, QuidelOrtho announced in June 2025 a strategy to accelerate growth in point-of-care molecular diagnostics by intending to acquire full ownership of LEX Diagnostics for approximately $100 million upon U.S. FDA clearance expected in late 2025 or early 2026, while discontinuing development of its Savanna platform; the company also completed a major debt refinancing in August 2025, issuing $1.15 billion in 5-year Term Loan A, $1.45 billion in 7-year Term Loan B, a $100 million delayed draw facility and a $700 million revolving credit facility to extend maturities, reduce amortization and enhance financial flexibility.
QuidelOrtho to Report Second Quarter 2026 Financial Results
QuidelOrtho to Report Second Quarter 2026 Financial Results
Reasons to Add QuidelOrtho Stock in Your Portfolio for Now
Beyond Fentanyl: How the Drug Crisis Is Changing
Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm
Kaskela Law Firm Announces Investigation of QuidelOrtho Corp. (QDEL) and Encourages Long-Term QDEL Shareholders with Investment Losses to Contact the Firm
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
QuidelOrtho: Too Much Uncertainty Around Earnings Keeping Short-Interest Elevated
QuidelOrtho (QDEL) Moves 32.2% Higher: Will This Strength Last?
QuidelOrtho Appoints Micah Young as Chief Financial Officer
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Is QuidelOrtho Corp (QDEL) a Bargain After 3.3% Drop? GF Value Says Undervalued
Is the Options Market Predicting a Spike in QuidelOrtho Stock?
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies
A Look at QuidelOrtho Corp (QDEL) After 6.0% Gain -- GF Value $37.21 vs Price $13.06
When Blood Compatibility Becomes a Pregnancy Risk
QuidelOrtho to Participate in Upcoming June 2026 Investor Conferences